3
|
He Y, Yang P, Shi M, Zhong C, Peng H, Guo D, Chang X, Liu Y, Chen J, Wang A, Zhang Y, He J, Xu T, Zhu Z. Plasma Phenylacetylglutamine Levels and Prognosis of Ischemic Stroke: A Multicenter Prospective Study Based on the CATIS Trial. Stroke 2024; 55:2652-2660. [PMID: 39466896 DOI: 10.1161/strokeaha.124.048494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2024] [Revised: 09/04/2024] [Accepted: 09/18/2024] [Indexed: 10/30/2024]
Abstract
BACKGROUND Phenylacetylglutamine is implicated in platelet clotting and thrombosis, but its prognostic value in ischemic stroke remains unclear. We aimed to explore the associations of plasma phenylacetylglutamine levels with adverse outcomes after ischemic stroke in a multicenter prognostic cohort study. METHODS Our multicenter prognostic cohort study included 3564 Chinese patients with ischemic stroke from the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). All patients were followed up at 3 months after ischemic stroke onset. The primary outcome was the composite outcome of death or major disability (modified Rankin Scale score, 3-6) at 3 months after ischemic stroke. RESULTS During 3 months of follow-up, 877 participants experienced the primary outcome. After multivariate adjustment, each 500 ng/mL increase of phenylacetylglutamine was associated with a 7% (P=0.012), 6% (P=0.016), and 6% (P=0.028) increased risk of the primary outcome, major disability, and death, respectively. The odds ratios or hazard ratios in the highest versus the lowest quartile of plasma phenylacetylglutamine were 1.62 ([95% CI, 1.18-2.23]; Ptrend=0.001) for the primary outcome, 1.62 ([95% CI, 1.16-2.24]; Ptrend=0.001) for major disability, and 2.59 ([95% CI, 1.19-5.60]; Ptrend=0.025) for death, respectively. There was a significantly worse shift in the distribution of modified Rankin Scale score at 3 months with higher phenylacetylglutamine quartiles (Ptrend=0.003). Multiple-adjusted spline regression model showed a linear relationship between phenylacetylglutamine and primary outcome (P value for linearity<0.001). The addition of plasma phenylacetylglutamine to conventional risk factors significantly improved the risk reclassification for the primary outcome (net reclassification improvement, 19.34%; P<0.001; integrated discrimination improvement, 0.23%; P=0.019). CONCLUSIONS Elevated plasma phenylacetylglutamine levels at baseline were associated with increased risks of adverse clinical outcomes at 3 months after ischemic stroke, suggesting that phenylacetylglutamine may be a promising prognostic biomarker for ischemic stroke. Further studies are needed to investigate whether phenylacetylglutamine is a stroke-specific biomarker.
Collapse
Affiliation(s)
- Yu He
- Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China (Y.H., P.Y., M.S., C.Z., H.P., X.C., Y.L., A.W., Y.Z., T.X., Z.Z.)
| | - Pinni Yang
- Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China (Y.H., P.Y., M.S., C.Z., H.P., X.C., Y.L., A.W., Y.Z., T.X., Z.Z.)
| | - Mengyao Shi
- Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China (Y.H., P.Y., M.S., C.Z., H.P., X.C., Y.L., A.W., Y.Z., T.X., Z.Z.)
- Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (M.S., H.P., J.C., J.H., Z.Z.)
| | - Chongke Zhong
- Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China (Y.H., P.Y., M.S., C.Z., H.P., X.C., Y.L., A.W., Y.Z., T.X., Z.Z.)
| | - Hao Peng
- Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China (Y.H., P.Y., M.S., C.Z., H.P., X.C., Y.L., A.W., Y.Z., T.X., Z.Z.)
- Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (M.S., H.P., J.C., J.H., Z.Z.)
| | - Daoxia Guo
- School of Nursing, Suzhou Medical College of Soochow University, China (D.G.)
| | - Xinyue Chang
- Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China (Y.H., P.Y., M.S., C.Z., H.P., X.C., Y.L., A.W., Y.Z., T.X., Z.Z.)
| | - Yi Liu
- Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China (Y.H., P.Y., M.S., C.Z., H.P., X.C., Y.L., A.W., Y.Z., T.X., Z.Z.)
| | - Jing Chen
- Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (M.S., H.P., J.C., J.H., Z.Z.)
- Department of Medicine, Tulane University School of Medicine, New Orleans, LA (J.C., J.H.)
| | - Aili Wang
- Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China (Y.H., P.Y., M.S., C.Z., H.P., X.C., Y.L., A.W., Y.Z., T.X., Z.Z.)
| | - Yonghong Zhang
- Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China (Y.H., P.Y., M.S., C.Z., H.P., X.C., Y.L., A.W., Y.Z., T.X., Z.Z.)
| | - Jiang He
- Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (M.S., H.P., J.C., J.H., Z.Z.)
- Department of Medicine, Tulane University School of Medicine, New Orleans, LA (J.C., J.H.)
| | - Tan Xu
- Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China (Y.H., P.Y., M.S., C.Z., H.P., X.C., Y.L., A.W., Y.Z., T.X., Z.Z.)
| | - Zhengbao Zhu
- Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China (Y.H., P.Y., M.S., C.Z., H.P., X.C., Y.L., A.W., Y.Z., T.X., Z.Z.)
- Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (M.S., H.P., J.C., J.H., Z.Z.)
| |
Collapse
|
6
|
Zhang J, Yin Z, Xu Y, Wei C, Peng S, Zhao M, Liu J, Xu S, Pan W, Zheng Z, Liu S, Ye J, Qin JJ, Wan J, Wang M. Resolvin E1/ChemR23 Protects Against Hypertension and Vascular Remodeling in Angiotensin II-Induced Hypertensive Mice. Hypertension 2023; 80:2650-2664. [PMID: 37800344 DOI: 10.1161/hypertensionaha.123.21348] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2023] [Accepted: 09/18/2023] [Indexed: 10/07/2023]
Abstract
BACKGROUND Inflammation plays a critical role in the development of hypertension and vascular remodeling. Resolvin E1 (RvE1), as one of the specialized proresolving lipid mediators, promotes inflammation resolution by binding with a G protein-coupled receptor, ChemR23 (chemerin receptor 23). However, whether RvE1/ChemR23 regulates hypertension and vascular remodeling is unknown. METHODS Hypertension in mice was induced by Ang II (angiotensin II) infusion (750 ng/kg per minute), and RvE1 (2 µg/kg per day) was administered through intraperitoneal injection. Loss of ChemR23 was achieved by mice receiving intravenous injection of adeno-associated virus 9-encoding shRNA against ChemR23. RESULTS Aortic ChemR23 expression was increased in Ang II-induced hypertensive mice and that ChemR23 was mainly expressed on vascular smooth muscle cells (VSMCs). RvE1 lowered blood pressure, reduced aortic media thickness, attenuated aortic fibrosis, and mitigated VSMC phenotypic transformation and proliferation in hypertensive mice, which were all reversed by the knockdown of ChemR23. Moreover, RvE1 reduced the aortic infiltration of macrophages and T cells, which was also reversed by ChemR23 knockdown. RvE1 inhibited Ccl5 expression in VSMCs via the AMPKα (AMP-activated protein kinase α)/Nrf2 (nuclear factor E2-related factor 2)/canonical NF-κB (nuclear factor κB) pathway, thereby reducing the infiltration of macrophages and T cells. The AMPKα/Nrf2 pathway also mediated the effects of RvE1 on VSMC phenotypic transformation and proliferation. In patients with hypertension, the serum levels of RvE1 and other eicosapentaenoic acid-derived metabolites were significantly decreased. CONCLUSIONS RvE1/ChemR23 ameliorated hypertension and vascular remodeling by activating AMPKα/Nrf2 signaling, which mediated immune cell infiltration by inhibiting the canonical NF-κB/Ccl5 pathway, and regulated VSMC proliferation and phenotypic transformation. RvE1/ChemR23 may be a potential therapeutic target for hypertension.
Collapse
Affiliation(s)
- Jishou Zhang
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Zheng Yin
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Yao Xu
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Cheng Wei
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Shanshan Peng
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Mengmeng Zhao
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Jianfang Liu
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Shuwan Xu
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Wei Pan
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Zihui Zheng
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Siqi Liu
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Jing Ye
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Juan-Juan Qin
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Center for Healthy Aging, Wuhan University School of Nursing, China (J.-J.Q.)
| | - Jun Wan
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| | - Menglong Wang
- Department of Cardiology, Renmin Hospital, Department of Geriatrics, Zhongnan Hospital, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.-J.Q., J.W., M.W.)
- Cardiovascular Research Institute, Wuhan University, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
- Hubei Key Laboratory of Cardiology, Wuhan, China (J.Z., Z.Y., Y.X., C.W., S.P., M.Z., J.L., S.X., W.P., Z.Z., S.L., J.Y., J.W., M.W.)
| |
Collapse
|